摘要
评价去甲肾上腺素(NA)治疗I型HRS的有效性和安全性。对14例I型HRS,其SCr为(363．7±64．2) μmol／1,持续静滴NA(0．1-0．5)μg·kg-1·min-1,直至HRS逆转(SCr<132．5μmol／L)或病人出现副反应或最长疗程15 天。结果8例(57．1％)HRS逆转,其SCr从(384．9±49．4)μmoL／L下降到(107．0±21．5)μmoL／L(P<0．001),BUN从 (18．1±3．3)mmol／L下降到(9．1±2．0)mmoL／L(P<0．001),尿钠从(6．9±2．0)mmol／24h升高到(35．1±6．3)mmol／24h (P<0．001),MAP从(63.8±5．2)mmHg提高到(77．6±4．1)mmHg(P<0．001)。所有患者治疗前后肝功能无明显改变。NA治疗I型HRS近期疗效明显,安全,可行性强。
The aim of this study was to evaluate the efficacy and safety of noradrenalin （NA） in the treatment of type 1 HRS. Four- teen cirrhotic with type 1 HRS patients, whose SCr （363.7 ± 64.2μmol/L） were treated with intravenous NA （0.1-0.5）μg·kg^-1·min^-1） until SCr decreased below 132.5μmol/L, or adverse events prevented further treatment, or for a maximum of 15 days. Reversal of HRS was observed in 8 of 14 patients （57.1%） after treatment. Among these patients： SCr levels fell from （384.9±49.4μmol/L） to （107.0±21.5μmol/L） （P〈0.001）, BUM fell from （18.1 ±3.3mmol/L） to （9.1 ＋ 2.0mmol/L） （ P 〈 0.001 ）, and urinary sodium output increased from （ 6.9 ＋ 2.0mmol/24h） to （35.1 ± 6.3mmol/24h ） （ P 〈 0.001 ）, MAP increased from （63.8±5.2mmHg） to （77.6 ± 4. lmmHg） （P 〈 0.001 ）. But there Was no significant difference between liver functions among all 14 patients neither before nor after treatmen. NA is effective and safe for the treatment of type 1 HRS, expecially as bridage to liver transplantion.
出处
《临床肝胆病杂志》
CAS
2005年第6期358-359,共2页
Journal of Clinical Hepatology
